← Leaderboards
Hongpeng Jia
Johns Hopkins University
$3,826,476
Attributed
$3,826,476
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,826,476 · 2
By mechanism
R01$2,934,846 · 1
R21$891,630 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Bryan J McVerry$2,744,011
- Mohammad Obaidul Hoque$2,723,149
- David Sidransky$59,922,938
- Christopher P O'Donnell$9,989,208
- Srinivasan Yegnasubramanian$11,365,706
Others in their field
Other Emerging Leaders on “Methodology”
- Yunda Huang · Fred Hutchinson Cancer Center$71,037,589
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$65,825,458
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Stuart Hellyar Hellyar$34,175,230
- Thomas Denny · Duke University$32,183,891
Research focus
MethodologyInflammatory ResponseNovel TherapeuticsClinically RelevantLung DiseasesMouse ModelPhysiologicalPreventPre-ClinicalMolecularRenin-Angiotensin SystemNeutrophilReagentHost DefenseImpairmentInsightPublic HealthOrganoidsBlood PressureRegulationLungInflammationGene TargetingSignal Pathway
Grant awards (9)
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection$546,821
R01 · FY2024 · AI · contact PI
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection$546,821
R01 · FY2023 · AI · contact PI
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection$546,821
R01 · FY2022 · AI · contact PI
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection$578,890
R01 · FY2021 · AI · contact PI
New ACE2 activator and its prodrug as novel therapeutic reagents for inflammatory pulmonary diseases$204,688
R21 · FY2021 · AI · contact PI
Supplement to "New ACE2 activator and its prodrug as novel therapeutic regents for inflammatory pulmonary diseases"$202,068
R21 · FY2021 · AI · contact PI
The role of ACE2 in Influenza viral infection mediated immune compromise and subsequent bacterial lung infection$715,493
R01 · FY2020 · AI · contact PI
New ACE2 activator and its prodrug as novel therapeutic reagents for inflammatory pulmonary diseases$245,625
R21 · FY2020 · AI · contact PI
New ACE2 activator and its prodrug as novel therapeutic reagents for inflammatory pulmonary diseases$239,249
R21 · FY2020 · AI · contact PI